Rep. Jefferson Shreve Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $50,001 and $100,000 in Abbott Laboratories stock on May 12th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Hubbell (NYSE:HUBB) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of Trane Technologies (NYSE:TT) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of NiSource (NYSE:NI) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of Johnson & Johnson (NYSE:JNJ) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of AppLovin (NASDAQ:APP) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of Fiserv (NYSE:FI) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of CNO Financial Group (NYSE:CNO) on 5/12/2025.
• Sold $50,001 – $100,000 in shares of Cboe Global Markets (NASDAQ:CBOE) on 5/12/2025.
• Sold $15,001 – $50,000 in shares of Lam Research (NASDAQ:LRCX) on 5/12/2025.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $127.32 on Friday. The company’s 50 day simple moving average is $131.78 and its 200 day simple moving average is $130.36. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.27. Abbott Laboratories has a 1 year low of $107.11 and a 1 year high of $141.23. The stock has a market capitalization of $221.52 billion, a price-to-earnings ratio of 15.95, a price-to-earnings-growth ratio of 2.39 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. During the same quarter in the previous year, the firm earned $1.14 EPS. Abbott Laboratories’s revenue was up 7.4% on a year-over-year basis. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ABT shares. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and increased their target price for the stock from $143.00 to $145.00 in a report on Friday, July 18th. BTIG Research dropped their price objective on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, July 18th. Leerink Partners began coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They set a “market perform” rating and a $143.00 target price on the stock. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Raymond James Financial cut their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $144.47.

Institutional Investors Weigh In On Abbott Laboratories

A number of institutional investors have recently modified their holdings of the company. Norges Bank bought a new position in shares of Abbott Laboratories in the 4th quarter worth about $2,373,461,000. Nuveen LLC acquired a new stake in Abbott Laboratories during the first quarter worth approximately $1,658,180,000. T. Rowe Price Investment Management Inc. increased its holdings in Abbott Laboratories by 383.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,358,698 shares of the healthcare product maker’s stock worth $945,453,000 after purchasing an additional 6,628,310 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $635,056,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Abbott Laboratories by 15,420.4% during the 1st quarter. GAMMA Investing LLC now owns 5,102,648 shares of the healthcare product maker’s stock worth $676,866,000 after buying an additional 5,069,771 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.